NCT04995419View on ClinicalTrials.gov

A Study to Evaluate Enfortumab Vedotin (ASG-22CE) in Chinese Participants With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Platinum-containing Chemotherapy and Programmed Cell Death Protein-1 ( PD 1) / (Programmed Death Ligand-1 (PD-L1) Inhibitor Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 22, 2021

Primary Completion Date

May 13, 2022

Study Completion Date

August 27, 2025

Conditions
Metastatic Urothelial Cancer
Interventions
DRUG

Enfortumab vedotin

Intravenous Infusion

Trial Locations (7)

Unknown

Site CN86001, Beijing

Site CN86009, Changsha

Site CN86002, Guangzhou

Site CN86006, Hangzhou

Site CN86007, Nanjing

Site CN86004, Shanghai

Site CN86003, Wuhan

All Listed Sponsors
collaborator

Seagen Inc.

INDUSTRY

lead

Astellas Pharma China, Inc.

INDUSTRY

NCT04995419 - A Study to Evaluate Enfortumab Vedotin (ASG-22CE) in Chinese Participants With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Platinum-containing Chemotherapy and Programmed Cell Death Protein-1 ( PD 1) / (Programmed Death Ligand-1 (PD-L1) Inhibitor Therapy | Biotech Hunter | Biotech Hunter